Stocks and Investing
Stocks and Investing
Wed, June 14, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Reiterated (ACRS) at Strong Buy and Held Target at $43 on, Jun 14th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy and Held Target at $43 on, Jun 14th, 2023.
Raghuram has made no other calls on ACRS in the last 4 months.
There are 2 other peers that have a rating on ACRS. Out of the 2 peers that are also analyzing ACRS, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Corinne Jenkins of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $21 on, Tuesday, March 7th, 2023
- Julian Harrison of "BTIG" Maintained at Strong Buy with Decreased Target to $29 on, Tuesday, March 7th, 2023
Contributing Sources